Integra LifeSciences Holdings Corporation IART
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.84% | 1.60% | 1.24% | 1.53% | 4.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.84% | 1.60% | 1.24% | 1.53% | 4.99% |
| Cost of Revenue | 3.29% | 3.15% | 6.27% | 9.91% | 9.63% |
| Gross Profit | -0.97% | 0.45% | -2.29% | -4.15% | 1.80% |
| SG&A Expenses | 23.58% | 24.81% | 24.52% | 24.50% | 5.31% |
| Depreciation & Amortization | 1.15% | 0.73% | 0.94% | 5.12% | 10.02% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.47% | 26.58% | 27.93% | 29.98% | 6.87% |
| Operating Income | 34.52% | 45.37% | 28.76% | 17.24% | -8.71% |
| Income Before Tax | 104.09% | 99.97% | -1,145.00% | -2,990.05% | -4,474.80% |
| Income Tax Expenses | 118.62% | 112.14% | -184.50% | -316.43% | -829.04% |
| Earnings from Continuing Operations | 102.63% | 98.55% | -1,612.31% | -7,338.77% | -7,469.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 102.63% | 98.55% | -1,612.31% | -7,338.77% | -7,469.30% |
| EBIT | 34.52% | 45.37% | 28.76% | 17.24% | -8.71% |
| EBITDA | 28.42% | 34.49% | 29.25% | 25.01% | 4.57% |
| EPS Basic | 102.60% | 98.55% | -1,616.49% | -7,553.52% | -7,247.67% |
| Normalized Basic EPS | 8.14% | 9.12% | -17.86% | -33.27% | -25.15% |
| EPS Diluted | 102.55% | 98.54% | -1,609.44% | -7,417.75% | -7,030.35% |
| Normalized Diluted EPS | 7.46% | 8.84% | -17.86% | -33.27% | -25.15% |
| Average Basic Shares Outstanding | 0.68% | 0.57% | 0.14% | -0.43% | -1.04% |
| Average Diluted Shares Outstanding | 1.35% | 0.86% | 0.14% | -0.43% | -1.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |